Clinical Trial: SRT Combined With Envafolimab and Endostar in the First-line Treatment of Advanced NSCLC

U.S., Sept. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07818304) titled 'SRT Combined With Envafolimab and Endostar in the First-line Treatment of Advanced NSCLC' on Sept. 08.

Brief Summary: This is a prospective, single-arm phase II clinical study. It intends to evaluate the efficacy and safety of stereotactic radiation therapy (SRT) combined with envafolimab and endostar as first-line treatment in stage IV non-small cell lung cancer (NSCLC) patients without actionable EGFR/ALK/ROS1 driver gene alterations and with PD-L1 TPS >= 1%. A total of 61 eligible participants will receive combination treatment of stereotactic radiotherapy, envafolimab and endostar. Tumor response will be evaluated every 6 weeks...